[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aclarion Inc (ACON)

Aclarion Inc (ACON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,150
  • Shares Outstanding, K 2,462
  • Annual Sales, $ 80 K
  • Annual Income, $ -7,230 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.18
  • Price/Sales 110.80
  • Price/Cash Flow N/A
  • Price/Book 0.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.55
  • Number of Estimates 1
  • High Estimate $-1.55
  • Low Estimate $-1.55
  • Prior Year $-9.32
  • Growth Rate Est. (year over year) +83.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.97 +8.42%
on 04/13/26
3.94 -18.27%
on 04/09/26
-0.35 (-9.80%)
since 04/02/26
3-Month
2.41 +33.61%
on 02/17/26
3.94 -18.27%
on 04/09/26
+0.86 (+36.44%)
since 02/05/26
52-Week
2.34 +37.61%
on 02/05/26
12.03 -73.23%
on 10/13/25
-3.93 (-54.96%)
since 05/05/25

Most Recent Stories

More News
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

BROOMFIELD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc.,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologies Expansion of commercial team reflects increasing...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Announces $2.5 Million Stock Repurchase Plan

BROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc .,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company leveraging biomarkers...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain

Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Receives Pinnacle Award for AI Innovation

Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) --...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Announces Agreement with Weill Cornell Medicine

BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc.,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 ...

ACONW : 0.0307 (-9.17%)
ACON : 3.22 (-2.72%)

Business Summary

Aclarion Inc. is a healthcare technology company which leverages Magnetic Resonance Spectroscopy and a proprietary biomarker to optimize clinical treatments. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed...

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.53
1st Resistance Point 3.42
Last Price 3.22
1st Support Level 3.24
2nd Support Level 3.16
3rd Support Level 3.05

See More

52-Week High 12.03
Fibonacci 61.8% 8.33
Fibonacci 50% 7.19
Fibonacci 38.2% 6.04
Last Price 3.22
52-Week Low 2.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.